Hi, I am using cuffdiff on single end illumina data. I naturally get a lot more significantly differentially expressed genes if I lower my threshold from 500 to 300, for example. When I use the default 500, much of my data comes out with NOTEST. What is an acceptable -c value to use to still find significantly differentially expressed genes?
-
-
I'm not going to claim to be an expert on just how to manipulate the code Cuffdiff uses, but it seems to me 500 is very high unless you have some ridiculous coverage. I had the same issues even with relatively large amounts of total RNA (5-10 ug) used and with genes I know have good expression levels from other experiments. So I cut the threshold down to 250. The P-values for most called differences where still way below .05. I know you run into alpha error inflation, because you're running these test 20000 time or more, depending on which genome you're working with, but you have to balance those false positive reportings with the false negatives for having the cutoff too high.
Anyway, I'm betting you're going to have to do replicates somehow regardless, so I rather set the cuttoff too low for RNA-seq, then shrink that list down with what ever kind of validation you're doing. -
Thank you very much for your response. I have actually changed my -c option to 0, seeing that there are genes with a smaller amount of reads that still can be differentially expressed. Can anyone comment to this approach, or if I am getting a lot of false values?
Thanks again!Comment
-
-c 0
I have also set this parameter to zero and lowered my FDR to reduce false discovery. I believe the key to analyzing this data is to realize that there are no absolutes and that we are creating a model and fitting the data as best as possible to this model. Be aware of your assumptions and the pitfalls of those assumptions and get into the data and work with it. Patterns will emerge and from that you can develop testable hypotheses.Comment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM
Comment